

Expanding evidence for CDK4/6 inhibitors in HR+/HER2- breast cancer:

From clinical trials to clinical practice



Saturday 7 December 2024



12:45-14:15 (SGT)



Hall 404, Level 4,
Suntec Singapore Convention
and Exhibition Centre, Singapore

Faculty



Dr. Yoon Sim Yap
Chair

Associate Professor,
National Cancer Centre Singapore
Singapore



Dr. Dejan Juric

Professor,
Massachusetts General Hospital,
Harvard Medical School
Boston, MA USA



Dr. Zefei Jiang

Professor,
Fifth Medical Center of Chinese
PLA General Hospital
Beijing, China

Agenda

Welcome and introduction

Unmet need for patients with HR+/HER2-
early breast cancer

Patient selection and clinical outcomes of
CDK4/6is in HR+/HER2- early breast cancer

Clinical guidance on use of CDK4/6is in
HR+/HER2- advanced breast cancer

Applying CDK4/6i data to patient management
in HR+/HER2- advanced breast cancer

Key takeaways and live Q&A

This event is organized and funded by Novartis.

The opinions and views expressed in this slide deck are those of the presenters and do not necessarily constitute the opinions or recommendations of Novartis. This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. This presentation is accurate at the time of presentation. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.